Dr Jing Pan, of Beijing Boren Hospital, Beijing, P.R. China, discusses a new anti-CD22 CAR T-cell immunotherapy for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Dr Pan explains how this exciting study evaluated humanized CD22-specific CAR T-cell therapy for patients who had failed multiple lines of treatment, including allo-HCT and CD19-targeted CAR T-cell therapy. He covers the promising results and highlights how this new therapy gives otherwise untreatable patients a new hope. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.